Ranibizumab versus aflibercept for macular edema due to central retinal vein occlusion: 18-month results in real-life data

  • Dan Călugăru
  • Mihai Călugăru
Letter to the Editor

Dear Editor:

We would to address several challenges that have arisen from the study by Chatziralli et al. [1], which can be specifically summarized below.

Several relevant data are missing from the study (Table 1).
Table 1

Missing data from the article by Chatziralli et al. [1]


Age stratification: ≤ 50 years/> 50 years

Mean and median duration of CRVO at presentation

Proportion of patients with a duration <1 month of CRVO

Diagnostic criteria for ischemic CRVO when intraretinal hemorrhages prevented a clear angiographic evaluation of the retinal capillary nonperfusion zones

Proportion of patients with subretinal/sub RPE fluid at presentation and at the end of the study

Prevalence of vitreoretinal interface abnormalities (e.g., vitreomacular adhesion/traction and epiretinal membranes) at enrollment and at month 18

The qualitative status of the three outer retinal layers (e.g., the external limiting membrane band, the interdigitation zone, and the retinal pigment epithelial...


Macular Edema Ranibizumab Aflibercept Retinal Vein Occlusion Choroidal Thickness 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Compliance with ethical standards

Conflict of interest

All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.


All authors have completed and submitted the ICMJE form for disclosure of potential conflicts of interest. There are no financial disclosures. Both authors (D.C and M.C) were involved in the design and conduct of the study; collection, management, analysis and interpretation of the data; and preparation, review or approval of the manuscript.

The authors have full control of the primary data and they agree to allow Graefe’s Archive for Clinical and Experimental Ophthalmology to review their data if requested.


  1. 1.
    Chatziralli I, Theodossiadis G, Moschos MM, Mitropoulos P, Theodossiadis P (2017) Ranibizumab versus aflibercept for macular edema due to central retinal vein occlusion: 18-month results in real-life data. Graefes Arch Clin Exp Ophthalmol. doi: 10.1007/s00417-017-3613-1 Google Scholar
  2. 2.
    Freund KB, Korobelnik JF, Deveny R et al (2015) Treat-and extend regimens with anti-VEGF agents in retinal diseases. Retina 35:1489–1506CrossRefPubMedGoogle Scholar
  3. 3.
    Gover S, Murthy RK, Brar VS, Chalam KV (2009) Normative data for macular thickness by high-definition spectral-domain optical coherence tomography (Spectralis). Am J Ophthalmol 148:266–271CrossRefGoogle Scholar
  4. 4.
    Papadopoulos N, Martin J, Ruan Q, Rafique A (2012) Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF trap, ranibizumab and bevacizumab. Angiogenesis 15:171–185CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Gharbiya M, Cruciani F, Mariotti C, Grandinetti F, Marenco M, Cacace V (2015) Choroidal thickness changes after intravitreal antivascular endothelial growth factor therapy for age-related macular degeneration: ranibizumab versus aflibercept. J Ocul Pharmacol Ther 31:357–362CrossRefPubMedGoogle Scholar
  6. 6.
    Julien S, Biesemeier A, Taubitz T, Schraermeyer U (2014) Different effects on intravitreally injected ranibizumab and aflibercept on retinal and chorodial tissues of monkey eyes. Br J Ophthalmol 98:813–825CrossRefPubMedGoogle Scholar
  7. 7.
    Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, Saroj N, Murahashi WY, Rubio RG (2011) Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase lll study. Ophthalmology 118:2041–2049CrossRefPubMedGoogle Scholar
  8. 8.
    Heier JS, Clark WL, Boyer DS, Brown DM, Vitti R, Berliner AJ, Kazmi H, Ma Y, Stemper B, Zeitz O, Sanbrink R, Haller JA (2014) Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the Copernicus study. Ophthalmology 121:1414–1420CrossRefPubMedGoogle Scholar
  9. 9.
    Ogura Y, Roider J, Korobelnik JF, Holtz FG, Simader C, Schmidt-Erfurth U, Vitti R, Berliner AJ, Hiemeyer F, Stemper B, Zeitz O, Sandbrink R, Galileo study group (2014) Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 Galileo study. Am J Ophthalmol 158:1032–1038CrossRefPubMedGoogle Scholar
  10. 10.
    Călugăru D, Călugăru M (2015) Intravitreal bevacizumab in acute central/hemicentral retinal vein occlusions: three-year results of a prospective clinical study. J Ocul Pharmacol Ther 31:78–86CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  1. 1.Department of OphthalmologyUniversity of Medicine Cluj-Napoca/RomaniaCluj-NapocaRomania

Personalised recommendations